Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2001

View Archived Issues

Synthetic peptide-based treatment for MS completes phase II trial in Canada

Tracleer NDA approvable, says FDA

Pivotal trial to begin soon for inhalable therapy for hereditary emphysema

Collagenase product for Dupuytren's disease heads for pivotal trials

Orion drops development of gel formulation of progestin

XTL continues to build strong infectious disease therapeutic pipeline

M-40403 improves diabetic vascular dysfunction and nerve damage

Levodopa with physiotherapy may improve motor recovery in stroke

Novel class of small nonpeptidyl compounds selectively inhibit malarial plasmepsins

Elastase inhibitors such as elafin may have clinical utility in intimal hyperplasia

Abbott presents new research findings in the area of protein farnesyltransferase inhibitors

New chemical series from American Cyanamid inhibits TACE and MMPs

Inhibitors of uPA binding and use as antitumor agents discussed by Roche

Pfizer scientists identify a series of CCR1 antagonists

Use of metabotropic glutamate receptor potentiators discussed by Lilly

Ortho-McNeil reports substituted amino acids that inhibit neutral sphingomyelinase activity

Animal studies support development of pyridoxamine for diabetic complications

Bradykinin B2 receptor modulators described in patent by Neurogen group

Tumor-imaging agents with selective affinity for vitronectin receptors

Inhibitex enters into partnership with Wyeth Lederle Vaccines

Negative results obtained in phase II GPG study

Broad development program under way for siplizumab

Enrollment of patients completed for phase III INS-365 Ophthalmic clinical program

FDA grants priority review status to etanercept for treatment of psoriatic arthritis

Optimization of anti-IL-9 antibody initiated

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...